Conexeu Sciences is advancing its investigational CXU™ tissue-restoration platform into medical aesthetics, targeting large-volume body contouring and restoration of the breasts, hips, and buttocks. The company has completed its 12-month P.R.O.O.F. preclinical study, which evaluated CXU™ in a large-volume model, restoring roughly 200cc, close to a full cup size. Conexeu aims to establish a new category called bioregeneration, pairing meaningful volume restoration with tissue regeneration, and plans a 510(k) submission in the first quarter of 2027. The breast implant market is projected to grow from $2.21 billion to $3.21 billion by 2030, while the buttock augmentation market is expected to expand from $2.99 billion in 2023 to $11.72 billion by 2030. GLP-1 adoption is driving demand, with the related aesthetics opportunity projected to nearly triple from roughly $0.7 billion to $2.0 billion by 2030.
Conexeu Sciences Inc. Common StockPositive preclinical study results and planned 510(k) submission for CXU platform targeting large-volume body restoration
AbbVie Inc